Gerald Beaney invests further in CRISM Therapeutics, revealing confidence in the company's potential.

In a move that radiates confidence, Gerald Beaney, a non-executive director at CRISM Therapeutics Corporation, has invested further in the company by acquiring an additional 20,182 ordinary shares.

Beaney purchased the shares at a price of 9.88 pence each, an investment decision presenting an increase in his voting rights within the company. The purchase now means that Beaney holds a total of 45,182 ordinary shares. As a result of this acquisition, Beaney’s stake in CRISM Therapeutics represents approximately 0.14% of the company’s total issued share capital, which stands at 32,678,312 shares.

The deal, which occurred off-market, was conducted outside a typical trading venue. This move by Beaney showcases unwavering belief in the company’s potential and may pique the interest of other investors.

Indeed, Beaney’s investment can be seen as a compelling vote of confidence in CRISM Therapeutics, which may stimulate further market interest in the corporation’s prospects and trajectory.